LPCN

Lipocine Inc

Add to Watchlist

Advanced Chart

2.910

-0.07(-2.349%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

2.980

Open

2.980

VWAP

2.91

Vol

14.86K

Mkt Cap

15.77M

Low

2.8647

Amount

43.26K

EV/EBITDA(TTM)

Total Shares

5.35M

-1.79M

EV/OCF(TTM)

P/S(TTM)

3.91

Lipocine Inc. is a biopharmaceutical company leveraging its proprietary technology platform to enable effective oral delivery of therapeutics. The Company’s clinical development candidates include: LPCN 1154, oral brexanolone, for the treatment of postpartum depression, LPCN 2101, for the treatment of epilepsy, LPCN 2203, an oral candidate targeted for the management of essential tremor, LPCN 2401, an oral proprietary anabolic androgen receptor agonist for improved body composition in obesity management, and LPCN 1148, for the management of decompensated cirrhosis. It is also developing LPCN 1107, for the prevention of preterm birth, LPCN 1154, for rapid relief of postpartum depression, and LPCN 1144, for the treatment of metabolic dysfunction-associated steatohepatitis. Its product candidate, TLANDO, is a novel oral prodrug of testosterone containing testosterone undecanoate developed by the Company.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

FY2025Q4

FY2026Q1

229.00K

+155.67%

-0.540

+22.73%

241.00K

-93.1%

-0.555

-268.18%

-0.550

+57.14%

Estimates Revision

The market is revising Upward the revenue expectations for Lipocine Inc. (LPCN) for FY2025, with the revenue forecasts being adjusted by 49.68% over the past three months. During the same period, the stock price has changed by -13.00%.

Revenue Estimates for FY2025

Revise Upward

+49.68%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+4.51%

In Past 3 Month

Stock Price

Go Down

-13.00%

In Past 3 Month

3 Analyst Rating

Wall Street analysts forecast LPCN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LPCN is 5.92 USD with a low forecast of 3.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

1 Hold

0 Sell

Moderate Buy

Current: 2.910

Low

3.00

Averages

5.92

High

8.00

Current: 2.910

Low

3.00

Averages

5.92

High

8.00

H.C. Wainwright

Yi Chen

initiated

2025-05-29

Reason

H.C. Wainwright

Yi Chen

Price Target

2025-05-29

initiated

Reason

H.C. Wainwright analyst Yi Chen assumed coverage of Lipocine with a Buy rating and $8 price target. Lipocine's first commercialized product, Tlando, an oral treatment indicated for testosterone replacement therapy, was approved by the FDA in 2022 and its current lead pipeline candidate is LPCN 1154, which is a rapid onset, oral formulation of the neuroactive steroid brexanolone for the treatment of postpartum depression, the analyst tells investors. If successfully developed, LPCN 1154 could "bring significant value to the company," says the analyst, who notes that the firm's current valuation is primarily based on market prospects for LPCN 1154.

Alliance Global Partners

Scott Henry

Strong Buy

Initiates

$10

2024-09-24

Reason

Alliance Global Partners

Scott Henry

Price Target

$10

2024-09-24

Initiates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Lipocine Inc (LPCN.O) is -1.36, compared to its 5-year average forward P/E of -5.07. For a more detailed relative valuation and DCF analysis to assess Lipocine Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-5.07

Current PE

-1.36

Overvalued PE

-2.06

Undervalued PE

-8.08

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.08

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.36

Undervalued EV/EBITDA

-0.19

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

15.42

Current PS

24.02

Overvalued PS

33.57

Undervalued PS

-2.73

Financials

Annual

Quarterly

FY2025Q2

YoY :

+595.42%

622.85K

Total Revenue

FY2025Q2

YoY :

-26.98%

-2.40M

Operating Profit

FY2025Q2

YoY :

-28.12%

-2.21M

Net Income after Tax

FY2025Q2

YoY :

-28.07%

-0.41

EPS - Diluted

FY2025Q2

YoY :

-24.48%

-1.89M

Free Cash Flow

FY2025Q2

YoY :

0.00%

100.00

Gross Profit Margin - %

FY2025Q2

YoY :

+22.50%

-120.64

FCF Margin - %

FY2025Q2

YoY :

-89.66%

-354.13

Net Margin - %

FY2025Q2

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

0.0

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

LPCN News & Events

Events Timeline

2025-08-05 (ET)

2025-08-05

08:04:21

Lipocine reports Q2 EPS (41c) vs. (57c) last year

2025-06-26 (ET)

2025-06-26

08:04:42

Lipocine says first patient dosed in Phase 3 clinical trial of LPCN 1154

2025-06-09 (ET)

2025-06-09

08:10:05

Lipocine announces filing of NDA for TLANDO in Canada

News

1.0

08-26PRnewswire

Lipocine Announces LPCN 2101 Abstracts Accepted for Presentation at AES 2025

9.5

08-05PRnewswire

Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2025

4.0

06-27Benzinga

HC Wainwright & Co. Reiterates Buy on Lipocine, Maintains $8 Price Target

People Also Watch

Calidi Biotherapeutics Inc

TOMI Environmental Solutions Inc

Kuke Music Holding Ltd

Willamette Valley Vineyards Inc

LightInTheBox Holding Co Ltd

FAQ

What is Lipocine Inc (LPCN) stock price today?

The current price of LPCN is 2.91 USD — it has decreased -2.35 % in the last trading day.

LPCN

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

LPCN News & Events

Events Timeline

News

People Also Watch

FAQ

What is Lipocine Inc (LPCN) stock price today?

What is Lipocine Inc (LPCN)'s business?

What is the price predicton of LPCN Stock?

What is Lipocine Inc (LPCN)'s revenue for the last quarter?

What is Lipocine Inc (LPCN)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Lipocine Inc (LPCN)'s fundamentals?

How many employees does Lipocine Inc (LPCN). have?

What is Lipocine Inc (LPCN) market cap?